RecruitingPhase 2NCT07287670

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Sponsor

Mediar Therapeutics

Enrollment

85 participants

Start Date

Apr 16, 2026

Study Type

INTERVENTIONAL

Conditions

Diffuse Cutaneous Systemic Sclerosis

Summary

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called MTX-474 and Placebo for people with diffuse cutaneous systemic sclerosis. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALMTX-474

Dosage level: 4 mg/kg Unit dose strength: 50mg/ml MTX-474 is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds the human EphrinB2 with high specificity and high affinity. MTX-474 is being developed as a therapy for patients with systemic sclerosis (SSc).

OTHERPlacebo

Placebo

Locations(58)

EncompaSSc site in Phoenix, AZ

Phoenix, Arizona, United States

EncompaSSc site in La Jolla, CA

La Jolla, California, United States

EncompaSSc site in Loma Linda, CA

Loma Linda, California, United States

University of California Los Angeles Scleroderma Center

Los Angeles, California, United States

NewportNativeMD, Inc.

Newport Beach, California, United States

EncompaSSc site in Palo Alto, CA

Palo Alto, California, United States

University of Colorado Center for Lungs/Breathing/Scleroderma Clinic

Aurora, Colorado, United States

Clinical Research of West Florida

Clearwater, Florida, United States

Sarasota Arthritis Center

Sarasota, Florida, United States

Clinical Research of West Florida

Tampa, Florida, United States

EncompaSSc site in Kansas City, KS

Kansas City, Kansas, United States

Johns Hopkins University

Baltimore, Maryland, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Boston Medical Center

Boston, Massachusetts, United States

EncompaSSc site in Minneapolis, MN

Minneapolis, Minnesota, United States

NYU Langone Health

Brooklyn, New York, United States

EncompaSSc site in Cleveland, OH

Cleveland, Ohio, United States

The University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

EncompaSSc site in Philadelphia, PA

Philadelphia, Pennsylvania, United States

EncompaSSc site in Pittsburgh, PA

Pittsburgh, Pennsylvania, United States

Stryde Research - DFW

Allen, Texas, United States

Baylor Scott & White Research Institute

Dallas, Texas, United States

EncompaSSc site in Houston, TX

Houston, Texas, United States

Griffith University (Clinical Trial Unit)

Southport, Queensland, Australia

EncompaSSc site in Woolloongabba, Australia

Woolloongabba, Queensland, Australia

Austin Health

Heidelberg, Victoria, Australia

EncompaSSc site in La Tronche, France

La Tronche, France

EncompaSSc site in Montpellier, France

Montpellier, France

EncompaSSc site in Paris, France

Paris, France

EncompaSSc site in Strasbourg, France

Strasbourg, France

EncompaSSc site in Toulouse, France

Toulouse, France

EncompaSSc site in Vandœuvre-lès-Nancy, France

Vandœuvre-lès-Nancy, France

EncompaSSc site in Ancona, Italy

Ancona, Italy

EncompaSSc site in Catania, Italy

Catania, Italy

EncompaSSc site in Genoa, Italy

Genoa, Italy

EncompaSSc site in Milan, Italy

Milan, Italy

EncompaSSc site in Modena, Italy

Modena, Italy

EncompaSSc site in Roma, Italy

Roma, Italy

EncompaSSc site in Groningen, Netherlands

Groningen, Netherlands

Aotearoa Clinical Trials

Auckland, New Zealand

Waikato Hospital

Hamilton, New Zealand

EncompaSSc site in Bydgoszcz, Poland

Bydgoszcz, Poland

EncompaSSc site in Nowa Sól, Poland

Nowa Sól, Poland

EncompaSSc site in Warszawa, Poland

Warsaw, Poland

EncompaSSc site in Warszawa, Poland

Warsaw, Poland

EncompaSSc site in Brasov, Romania

Brasov, Romania

EncompaSSc site in Bucharest, Romania

Bucharest, Romania

EncompaSSc site in Bucharest, Romania

Bucharest, Romania

EncompaSSc site in Timişoara, Romania

Timișoara, Romania

EncompaSSc site in Barcelona, Spain

Barcelona, Spain

EncompaSSc site in Barcelona, Spain

Barcelona, Spain

EncompaSSc site in Córdoba, Spain

Córdoba, Spain

EncompaSSc site in Malaga, Spain

Málaga, Spain

EncompaSSc site in Valencia, Spain

Valencia, Spain

EncompaSSc site in Walsgrave Coventry, UK

Coventry, United Kingdom

EncompaSSc site in Liverpool, UK

Liverpool, United Kingdom

EncompaSSc site in London, UK

London, United Kingdom

EncompaSSc site in Westcliff-on-Sea, UK

Westcliff-on-Sea, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07287670

Related Trials

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048128 locations

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT0692554214 locations

Controlling Hyperactive Immunity With Long-lived Lymphocytes

NCT074731546 locations

US Zamto-cel Autoimmune Diseases

NCT067088451 location

Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

NCT069362151 location